The fate of bone marrow edema after core decompression and bone marrow aspiration concentrate grafting for the hip Authors: Weiping Su, Boyan Ma, Wenjie Leng, Yixiao Pan, Wenxiu Zhang, Song Wu, Zhi Peng Published: 2025 ABSTRACT BackgroundBone marrow edema (BME) of the femoral head is a prevalent condition that can cause hip pain and is observed in patients as a standalone finding or in conjunction with degenerative or inflammatory conditions. There has been a lack of extensive study on the effectiveness of combining surgery with biological treatment for BME. The objective of this study was to evaluate the efficiency of core decompression (CD) with bone marrow aspirate concentrate (BMAC) augmentation in alleviating pain and enhancing the quality of life in patients with BME in the hip.Materials and methodsWe conducted a retrospective analysis of patients who underwent treatment for BME of the hip using CD combined with BMAC between June 2021 and July 2023. Inclusion criteria consisted of patients diagnosed with BME in the hip (presence of BME on T2-weighted MRI in the femoral head or neck with pain corresponding to the same compartment as the BME). The patients’ demographic information, presence of other medical conditions, body mass index (BMI), etiology, and assessments using the visual analog scale (VAS) and Harris hip score (HHS) were recorded. Pre- and postoperative radiographic imaging (XR) and magnetic resonance imaging (MRI) were analyzed.ResultsThis study included 28 patients (40 femoral heads) who underwent CD with BMAC grafting at our institution. Among these patients, 9 had normal or non-diagnostic radiographs, 11 were at ARCO stage Ⅰ, and 8 were at ARCO stage Ⅱ. The mean age at the time of operation was 45.21 years (SD 13.17, range 21–75), and the mean BMI was 24.61 (SD 3.75, range 16.6–32.05). The area of BME showed a significant decrease from 954.21 ± 224.68 mm2 to 162.21 ± 189.05 mm2 3 months following surgery (P < 0.001). The VAS showed a substantial reduction from 4.86 ± 1.24 points to 1.86 ± 1.27 points at 3 months post-surgery, and further decreased to 1 ± 1.68 points at 12 months post-surgery (P < 0.001). HHS increased from 48.14 ± 4.4 points to 72.79 ± 8.96 points at 3 months after surgery and further increased to 86.39 ± 11.82 points at 12 months after surgery (P < 0.001). Two patients experienced the resolution of BME 3 months following surgery, whereas 3 femoral heads of 3 patients with ARCO 2 stage collapsed.ConclusionTreatment of BME of the hip using CD combined with BMAC is effective and provides short-term pain relief for BME. Introduction Bone marrow edema (BME) is a radiological term first defined by Wilson et al. in 1988 [1]. It is characterized by the accumulation of interstitial fluid within the bone marrow space, most commonly in the femoral head and neck [2]. Clinically, BME presents with increasing hip discomfort and restricted range of motion (ROM), typically resolving spontaneously within 3 to 24 months [3, 4]. On MRI scans, BME of the hip is identified by water signals, appearing as low intensity on T1-weighted images and high intensity on T2-weighted images. The etiology and pathogenesis of BME are not fully understood, but it may lead to osteonecrosis of the femoral head (ONFH) [2]. Non-invasive therapies have been shown to reduce pain in BME patients, but the duration of pain relief and the extent of functional recovery remain unclear [5–7]. Core decompression (CD) is the most commonly used clinical technique for joint preservation in patients with ONFH [8, 9]. It effectively manages pain, prevents or slows further joint destruction, and significantly decreases bone marrow pressure [10, 11]. The CD has also been applied in BME and may be considered as a potential approach to improve symptoms and minimize MRI alterations [12]. It has been reported that cellular therapy can be achieved by enhancing CD with concentrated bone marrow aspirate concentrate (BMAC), aiming to transplant osteoprogenitor cells into the infarcted zone [13]. Promising outcomes have been observed in patients with ONFH when CD is combined with BMAC augmentation [14, 15]. However, the impact of CD with BMAC augmentation on BME in the hip remains unknown. The objective of this study was to evaluate the efficiency of CD with BMAC augmentation in alleviating pain and improving the quality of life in patients with BME in the hip. The results of this investigation may provide valuable insights into clinical management. Method Patients and study design The study was approved by the Institutional Review Board of the Third Xiangya Hospital of Central South University (N.2023-S111) on 13 March 2023 and was conducted in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability regulations. Inclusion criteria were: patients with a diagnosis of BME in the hip (presence of BME on T2-weighted MRI in the femoral head or neck with pain corresponding to the same compartment as the BME), a single surgeon, core decompression combined with BMAC grafting. The patient’s demographic information, presence of other medical conditions, body mass index (BMI), etiology, visual analog scale (VAS), and harris hip score (HHS) were documented. Pre- and postoperative radiographic imaging (XR) and magnetic resonance imaging (MRI) were analyzed. Surgical procedure Bone marrow harvest The bone marrow harvest procedure involves positioning the patient laterally. The posterior superior iliac crest is meticulously sterilized and covered with a sterile drape. A Jamshidi needle is percutaneously inserted into the posterior superior iliac crest. A quantity of 60 mL of bone marrow is obtained. Afterward, the bone marrow aspirate is deposited into the bone marrow processing system to produce 8 mL of BMAC. Core decompression Using C-arm fluoroscopy, multiple 2.0-mm-diameter Kirschner wires were inserted from the proximal lateral femur cortex through the bone marrow edema region in the femoral neck and femoral head. Utilizing intraoperative fluoroscopic visualization, adequate decompressions at the edema region were verified. The BMAC was injected through the cannulated drill and delivery system to the bone marrow edema region. Postoperative rehabilitation protocol The operative site of the hip was allowed to bear 50% of the weight post-surgery for 6 weeks. After this initial 6-week period, patients were permitted to progress to full weight-bearing. The use of crutches is mandatory throughout the entire 6-week recovery period. Patients were prescribed abductor strengthening exercises and provided with education on the importance of avoiding high-impact activities for a period of 1 year. Rehabilitation, which encompasses hip abductor strengthening exercises as well as range of motion exercises, should be initiated as soon as possible following surgery to facilitate the recovery process. Furthermore, a course of NSAIDs, bisphosphonates, and vitamin D supplements were administered over three months. Hip function evaluation The patient was followed up at 3, 6 and 12 months. The preoperative and postoperative VAS and HHS were assessed and analyzed independently to determine the disparities between the preoperative and postoperative periods. Complications, duration of postoperative pain relief, and the extent of bone marrow edema were recorded. Statistical analysis All data were compiled in Microsoft Office 365 Excel (Microsoft, Redmond, WA), and analyses were performed using PRISM (version 8; GraphPad, San Diego, CA). Continuous variables are represented by the mean ± standard deviation (SD). If test of normality of the data was passed, repeated-measures ANOVA with LSD test for pairwise comparisons between time points and paired samples t-test were used. In cases of violation of Mauchly’s sphericity assumption, a Greenhouse–Geisser correction was applied. Wilcoxon test was used for non-normally distributed data. Statistical significance was set at p<0.05. Results Baseline characteristics of patients This study included 28 patients who underwent CD with BMAC grafting at our institution. A total of 40 femoral heads were treated, consisting of 11 females (8 unilateral femoral heads and 3 bilateral femoral heads) and 17 males (14 unilateral femoral heads and 3 bilateral femoral heads). The average age at the time of surgery was 45.21 years (SD 13.17, range 21–75), and the average BMI was 24.61 (SD 3.75, range 16.6–32.05). The etiology, association research circulation osseous classification (ARCO) staging, follow-up period, and quantification are summarized in Table 1. Table 1The information on etiology, ARCO staging, and follow-up periodVariableNumberEtiology Traumatic0 Inflammatory or Infectious0 Steroid2 Alcohol3 Unknown23Sign and classification of osteonecrosis Normal or non-diagnostic radiograph9 ARCO Ⅰ11 ARCO Ⅱ8Mean Follow Up (months)30.32 Table 1The information on etiology, ARCO staging, and follow-up periodVariableNumberEtiology Traumatic0 Inflammatory or Infectious0 Steroid2 Alcohol3 Unknown23Sign and classification of osteonecrosis Normal or non-diagnostic radiograph9 ARCO Ⅰ11 ARCO Ⅱ8Mean Follow Up (months)30.32 The information on etiology, ARCO staging, and follow-up period Radiographic and clinical outcomes The area of BME decreased from 954.21 ± 224.68 mm2 (95% CI, 891.0 to 1104) before treatment to 162.21 ± 189.05 mm2 (95% CI, 76.00 to 167.0) three months following surgery (P < 0.001) (Fig. 1). The VAS showed a significant decrease from 4.86 ± 1.24 (95% CI, 4 to 5) points before surgery to 1.86 ± 1.27 (95% CI, 1 to 2) points (3 months after surgery) (P < 0.001) and 1 ± 1.68 (95% CI, 0 to 1) points (12 months after surgery) (P < 0.001). Before treatment, HHS was 48.14 ± 4.4 (95% CI, 46 to 50) points. It increased to 72.79 ± 8.96 (95% CI, 70 to 77) points (3 months after surgery) (P < 0.001) and 86.39 ± 11.82 (95% CI, 85 to 91) points (12 months after surgery) (P < 0.001). Two patients experienced the disappearance of BME 3 months following surgery, while 3 femoral heads of 3 patients with ARCO 2 stage collapsed in the follow-up period. The area of BME, VAS, HHS, and collapsed condition in each ARCO stage is summarized in Table 2 and Fig. 2. Fig. 1A 23-years-old man of BME affecting the hip after CD combined with BMAC, MRI (T2W-SPIR) image of coronal (A) and axial (B) view before operation, MRI (T2W-SPIR) image of coronal (C) and axial (D) view 3 month after operation A 23-years-old man of BME affecting the hip after CD combined with BMAC, MRI (T2W-SPIR) image of coronal (A) and axial (B) view before operation, MRI (T2W-SPIR) image of coronal (C) and axial (D) view 3 month after operation Table 2The area of BME, VAS, HHS, and collapsed conditionNormal or non-diagnostic radiograph (n = 9)ARCO Ⅰ (n = 11)ARCO Ⅱ (n = 8)Area of BME (mm2)Pre-operation834.88 ± 264.931058.25 ± 126.79993.88 ± 262.86Month 3349.25 ± 258.15***147 ± 70.97***43.75 ± 43.92*VASPre-operation4.25 ± 1.34.88 ± 1.255.38 ± 1.28Month 30.88 ± 1.55***1.61 ± 0.52**2.88 ± 0.83***Month 120.13 ± 2.3**0.63 ± 0.52***2.13 ± 0.35**HHSPre-operation47.75 ± 5.0448.75 ± 5.4447.13 ± 2.588Month 382.5 ± 3.89***72.63 ± 3.16***65.88 ± 7.08***Month 1293.13 ± 2.75**89.63 ± 4.81***76.38 ± 15.4*Collapsed003*p<0.05, **p<0.01, ***p<0.001 Table 2The area of BME, VAS, HHS, and collapsed conditionNormal or non-diagnostic radiograph (n = 9)ARCO Ⅰ (n = 11)ARCO Ⅱ (n = 8)Area of BME (mm2)Pre-operation834.88 ± 264.931058.25 ± 126.79993.88 ± 262.86Month 3349.25 ± 258.15***147 ± 70.97***43.75 ± 43.92*VASPre-operation4.25 ± 1.34.88 ± 1.255.38 ± 1.28Month 30.88 ± 1.55***1.61 ± 0.52**2.88 ± 0.83***Month 120.13 ± 2.3**0.63 ± 0.52***2.13 ± 0.35**HHSPre-operation47.75 ± 5.0448.75 ± 5.4447.13 ± 2.588Month 382.5 ± 3.89***72.63 ± 3.16***65.88 ± 7.08***Month 1293.13 ± 2.75**89.63 ± 4.81***76.38 ± 15.4*Collapsed003*p<0.05, **p<0.01, ***p<0.001 The area of BME, VAS, HHS, and collapsed condition *p<0.05, **p<0.01, ***p<0.001 Fig. 2The information of BME area, VAS, HHS in each ARCO stage, *p<0.05, **p<0.01, ***p<0.001 The information of BME area, VAS, HHS in each ARCO stage, *p<0.05, **p<0.01, ***p<0.001 Discussion In this study, we aim to identify the efficiency of CD combined with BMAC grafting for treating BME in the hip. BME of the femoral head is a prevalent condition that can cause hip pain and is observed in patients as an isolated finding or in conjunction with conditions such as inflammatory arthritis, inflammatory spondylitis, enthesitis, osteoarthritis, and fracture [16–18]. Most current literature primarily focused on interventions for the progression of femoral head osteonecrosis, with limited research investigating the treatment of BME caused by various factors [13, 19, 20]. The main finding of this study was that patients who underwent surgical treatment for BMEs of the hip using CD combined with BMAC, exhibited sustained improvements in pain and function that persisted in the subsequent 1 year. A widely reported discovery in the field of BME is the presence of compromised microcirculation, which results in reduced blood flow and oxygen supply to tissues, leading to ischemia and elevated pressure within the bone [21]. The CD can reduce the pressure in the affected area and increase the local blood supply. CD is a common surgical technique for treating ONFH [22, 23], but its role in alleviating the BME of the femoral head has been rarely mentioned. In this study, we used multiple drilling reaching into the area affected by BME. Autologous BMAC has demonstrated its effectiveness and safety compared to other bone grafting techniques [24, 25]. Based on our results, CD combined with BMAC effectively alleviated local BME in patients without osteonecrosis of the femoral head and those at ARCO Stage I. 3 months after the operation, MRI of most patients showed a significant reduction in the area of BME, with some patients experiencing complete resolution. The results are quite similar with the others. Bashaireh et al. reported that the pain score dropped significantly after hip drilling and the time needed for full recovery was 5.8 weeks for those who underwent hip drilling for core decompression and was 48.3 weeks for three patients who received conservative treatment [26]. For patients at ARCO Stage II, CD combined with BMAC reduced the extent of BME in several cases and effectively inhibited the progression of femoral head necrosis. However, in a minority of patients (three in this study), despite a slight reduction in the area of bone marrow edema, the disease progressed to femoral head collapse. Our findings are in line with others such as Hernigou et al. reported a percentage of progression of 37.9% (44/116 femoral heads) at a follow up of 5–10 years [27]. Three factors might contribute to the variability in outcomes following CD with BMAC treatment. Femoral head osteonecrosis is a highly heterogeneous disease with diverse etiologies and potential subtypes [28], CD with BMAC might only be effective for specific etiological subtypes of femoral head osteonecrosis. Moreover, there remain significant challenges in optimizing the harvesting and processing of bone marrow aspirate, determining the ideal number [29] and delivery method for transplanted cells, and enhancing the retention of transplanted cells at the target site [30]. Additionally, the composition of bone marrow aspirate concentrate varies among patients, potentially influencing treatment efficacy. Based on our findings, CD with BMAC can significantly reduce the extent of BME within three months postoperatively, and in some cases, achieve complete resolution. This outcome is notably faster than that reported for conservative treatments in other studies. This study has several limitations that need to be addressed. The first limitation is the lack of a control group. Future research should include a comparative analysis between single CD and CD combined with BMAC to clarify the specific effects of each surgical method on alleviating local BME. The second limitation is the relatively small sample size and short follow-up period. A study with a larger cohort and an extended follow-up period is necessary to determine the long-term efficacy of this treatment. Additionally, patients in our study received adjunctive pharmacological treatments (NSAIDs, bisphosphonates, and vitamin D supplements) to expedite recovery. While these medications aimed to enhance patient outcomes, their use introduces a confounding variable that may obscure the true therapeutic effect of the surgical procedure alone. Future studies should aim to isolate the impact of surgical intervention by controlling or minimizing the use of adjunctive therapies.